Neuropathic Pain - Pipeline Review, H2 2017

Date: December 29, 2017
Pages: 488
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N8DC6078A19EN
Leaflet:

Download PDF Leaflet

Neuropathic Pain - Pipeline Review, H2 2017
Neuropathic Pain - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.

Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 6, 24, 29, 1, 114, 27 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 1 molecules, respectively.

Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Neuropathic Pain - Overview
Neuropathic Pain - Therapeutics Development
Neuropathic Pain - Therapeutics Assessment
Neuropathic Pain - Companies Involved in Therapeutics Development
Neuropathic Pain - Drug Profiles
Neuropathic Pain - Dormant Projects
Neuropathic Pain - Discontinued Products
Neuropathic Pain - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Neuropathic Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Companies, H2 2017 (Contd.6), H2 2017
Products under Development by Companies, H2 2017 (Contd.7), H2 2017
Products under Development by Companies, H2 2017 (Contd.8), H2 2017
Products under Development by Companies, H2 2017 (Contd.9), H2 2017
Products under Development by Companies, H2 2017 (Contd.10), H2 2017
Products under Development by Companies, H2 2017 (Contd.11), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2017
Neuropathic Pain - Pipeline by AbbVie Inc, H2 2017
Neuropathic Pain - Pipeline by Abide Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Achelios Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2017
Neuropathic Pain - Pipeline by AnaBios Corp, H2 2017
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp, H2 2017
Neuropathic Pain - Pipeline by AngioChem Inc, H2 2017
Neuropathic Pain - Pipeline by Aptinyx Inc, H2 2017
Neuropathic Pain - Pipeline by Arena Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Astellas Pharma Inc, H2 2017
Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2017
Neuropathic Pain - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
Neuropathic Pain - Pipeline by BCI Pharma, H2 2017
Neuropathic Pain - Pipeline by BCN Peptides SA, H2 2017
Neuropathic Pain - Pipeline by Biogen Inc, H2 2017
Neuropathic Pain - Pipeline by Bionomics Ltd, H2 2017
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Co, H2 2017
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd, H2 2017
Neuropathic Pain - Pipeline by Cara Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Celgene Corp, H2 2017
Neuropathic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2017
Neuropathic Pain - Pipeline by Cerecor Inc, H2 2017
Neuropathic Pain - Pipeline by Chromocell Corp, H2 2017
Neuropathic Pain - Pipeline by Circuit Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by Colby Pharmaceutical Co, H2 2017
Neuropathic Pain - Pipeline by ConSynance Therapeutics Inc, H2 2017
Neuropathic Pain - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Neuropathic Pain - Pipeline by Cytogel Pharma LLC, H2 2017
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Neuropathic Pain - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2017
Neuropathic Pain - Pipeline by Dompe Farmaceutici SpA, H2 2017
Neuropathic Pain - Pipeline by Eisai Co Ltd, H2 2017

LIST OF FIGURES

Number of Products under Development for Neuropathic Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

2-BBB Medicines BV
AbbVie Inc
Abide Therapeutics Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Affectis Pharmaceuticals AG
AnaBios Corp
Anavex Life Sciences Corp
AngioChem Inc
Aptinyx Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Aucta Pharmaceuticals LLC
BCI Pharma
BCN Peptides SA
Biogen Inc
Bionomics Ltd
Bristol-Myers Squibb Co
Can-Fite BioPharma Ltd
Cara Therapeutics Inc
Celgene Corp
Centrexion Therapeutics Corp
Cerecor Inc
Chromocell Corp
Circuit Therapeutics Inc
Colby Pharmaceutical Co
ConSynance Therapeutics Inc
ContraVir Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Develco Pharma Schweiz AG
Dompe Farmaceutici SpA
Eisai Co Ltd
Eli Lilly and Co
Endece LLC
Evec Inc
Genecode AS
GL Pharm Tech Corp
Glialogix Inc
Grunenthal GmbH
GT Biopharma Inc
GW Pharmaceuticals Plc
Hydra Biosciences Inc
Immune Pharmaceuticals Inc
India Globalization Capital Inc
Intec Pharma Ltd
Integral Molecular Inc
IntelGenx Corp
Intellipharmaceutics International Inc
Ionis Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
JT Pharmaceuticals Inc
Knopp Biosciences LLC
Kolon Life Science Inc
KPI Therapeutics Inc
Lexicon Pharmaceuticals Inc
Lohocla Research Corp
Mapi Pharma Ltd
MD Biosciences GmbH
Medifron DBT Co Ltd
MEDRx Co Ltd
Medy-Tox Inc
Merck & Co Inc
Mitsubishi Tanabe Pharma Corp
Mundipharma International Ltd
Nanomerics Ltd
Neurim Pharmaceuticals Ltd
Neurocentrx Pharma Ltd
NeuroCycle Therapeutics GmbH
NeurOp Inc
Newron Pharmaceuticals SpA
Nippon Chemiphar Co Ltd
Nippon Zoki Pharmaceutical Co Ltd
NoNO Inc
Novartis AG
Novassay SA
Orexigen Therapeutics Inc
Orion Corporation
Patagonia Pharmaceuticals LLC
PeriphaGen Inc
Pfizer Inc
Pharmaleads SA
Phosphagenics Ltd
RaQualia Pharma Inc
Re-Pharm Ltd
Relmada Therapeutics Inc
Revance Therapeutics Inc
Rottapharm Biotech Srl
Saniona AB
Scilex Pharmaceuticals Inc
Shionogi & Co Ltd
Sunovion Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
Theranexus SAS
Toray Industries Inc
Torrent Pharmaceuticals Ltd
Trevena Inc
Vertex Pharmaceuticals Inc
Virobay Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Yooyoung Pharm Co Ltd
Yuhan Corp
Yungjin Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Skip to top


Visceral Pain - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 55 pages
Visceral Pain - Pipeline Review, H1 2018 US$ 2,000.00 Feb, 2018 · 51 pages
Ocular Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 70 pages

Ask Your Question

Neuropathic Pain - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: